Literature DB >> 31764902

Enhanced Recovery After Surgery: Concepts and Application to Total Shoulder Replacement.

Thomas W Wainwright1, Tikki Immins, Johannes H A Antonis, Richard Hartley, Robert G Middleton.   

Abstract

BACKGROUND: Enhanced Recovery After Surgery (ERAS) focuses on optimizing each element on a treatment pathway and encouraging the patient to actively engage in his or her recovery and rehabilitation. It requires collaboration across a multidisciplinary team and has been successful in improving patient outcomes, length of stay (LOS), and costs for a wide range of surgical procedures, including musculoskeletal surgeries such as total hip and total knee replacement.
PURPOSE: To examine the application of ERAS concepts to total shoulder replacement (TSR) surgery.
METHODS: Hospital Episode Statistics (HES) in England on LOS for TSR surgery were examined, and a review of literature on the use of ERAS concepts in TSR was undertaken.
RESULTS: Analysis of HES data suggested scope for improvement in reducing LOS. A review of the literature found some evidence of the use of ERAS concepts, particularly in multimodal pain management.
CONCLUSIONS: Future research is now required for ERAS procedure-specific components for TSR surgery.

Entities:  

Mesh:

Year:  2019        PMID: 31764902     DOI: 10.1097/NOR.0000000000000609

Source DB:  PubMed          Journal:  Orthop Nurs        ISSN: 0744-6020            Impact factor:   0.913


  2 in total

1.  Introduction of an enhanced recovery programme for total shoulder arthroplasty: report of a novel pathway.

Authors:  Marie L Morgan; Gareth R Davies-Jones; Edward F Ibrahim; Simon J Booker; Marcus Bateman; Amol A Tambe; David I Clark
Journal:  BMJ Open Qual       Date:  2021-10

2.  A nomogram to predict the risk of prolonged length of stay following primary total hip arthroplasty with an enhanced recovery after surgery program.

Authors:  Haosheng Wang; Tingting Fan; Wenle Li; Bo Yang; Qiang Lin; Mingyu Yang
Journal:  J Orthop Surg Res       Date:  2021-12-14       Impact factor: 2.359

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.